smh.com.au
🌐 75% Global Worthiness
CSL Profits Rise Despite Flu Vaccine Revenue Drop Amid US Vaccine Hesitancy
CSL reported a 7 percent increase in net profit to $US2.01 billion, but its flu vaccine unit, Seqirus, experienced a 9 percent revenue drop due to lower US vaccination rates in the 18-64 age group, amid rising vaccine skepticism and Robert F Kennedy Jr.'s potential appointment as US Health Secretary...
CSL Profits Rise Despite Flu Vaccine Revenue Drop Amid US Vaccine Hesitancy
CSL reported a 7 percent increase in net profit to $US2.01 billion, but its flu vaccine unit, Seqirus, experienced a 9 percent revenue drop due to lower US vaccination rates in the 18-64 age group, amid rising vaccine skepticism and Robert F Kennedy Jr.'s potential appointment as US Health Secretary...
Progress
40% Bias Score
Good Health and Well-being